Fixed-dose, weight-adjusted, unfractionated heparin was as effective and safe as low-molecular-weight heparin for venous thromboembolism

White, Richard H.
January 2007
ACP Journal Club;Jan/Feb2007, Vol. 146 Issue 1, p1
Academic Journal
The article cites a study on the treatment"of venous thromboembolism (VTE) patients, which was conducted by medical researcher C. Kearon and colleagues, and published in an issue of the "Journal of the American Medical Association." The study was concerned with the treatment of VTE patients with fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin. The study concluded that the major benefit of subcutaneous regular heparin is its low cost.


Related Articles

  • JAMA wants campaign on clinical alerts. Josefson, Deborah // BMJ: British Medical Journal (International Edition);11/29/97, Vol. 315 Issue 7120, p1399 

    Reports that the `Journal of the American Medical Association' is organizing a campaign of clinical alerts to ensure that patients benefit quickly from medical breakthroughs. Campaign's means of relaying messages across the country; Evidence that medical treatments reported in the literature...

  • Newer Anticoagulants for Venous Thromboembolism.  // American Family Physician;9/15/1996, Vol. 54 Issue 4, p1361 

    Presents the results of a meta-analysis conducted to determine the efficacy and safety of low-molecular-weight heparins compared with unfractioned heparin in patients with acute venous thromboembolism. Potential advantages of low-molecular-weight heparins over unfractioned heparins; Comparison...

  • Reviparin: A Review of its Efficacy in the Prevention and Treatment of Venous Thromboembolism. Wellington, K.; McClellan, K.; Jarvis, B. // Drugs;Jun2001, Vol. 61 Issue 8, p1185 

    Reviparin (reviparin sodium) is a low molecular weight heparin (LMWH) that catalyses the inactivation of factors Xa and IIa by binding to antithrombin, which ultimately leads to the inhibition of the clotting cascade. It is administered subcutaneously. Reviparin 7000 to 12 600 anti-XaIU/day was...

  • A clear head with fewer pills.  // U.S. News & World Report;4/17/95, Vol. 118 Issue 15, p88 

    Comments on a study in an April 1995 issue of `Journal of the American Medical Association.' Finding that patients who took trimethoprim/sulfamethoxazole (commonly prescribed for sinusitis in its generic form or as the brand-name Septra) for three days felt the same relief as those taking it...

  • JAMA Addresses Conflicts of Interest. Brichacek, Andra // Pharmaceutical Executive;Dec2000, Vol. 20 Issue 12, p75 

    Deals with the move of the `Journal of the American Medical Association' to address the issue of conflicts of interest among academic researchers and contributors to the periodical. Discussion on the issue of conflict of interest when a researcher has financial stake to a pharmaceutical company;...

  • Update on JAMA's Policy on Release of Information to the Public. Fontanarosa, Phil B.; Flanagin, Annette; DeAngelis, Catherine D. // JAMA: Journal of the American Medical Association;10/1/2008, Vol. 300 Issue 13, p1585 

    The author reflects on the policies of the "Journal of the American Medical Association" (JAMA), specifically the policies regarding the publication's previously published editorials and release of information to the public. Other topics include manuscripts submitted for evaluation, the...

  • ADOPT: Apixaban not superior to enoxaparin for thromboprophylaxis. Fisher, Stacey L.; Foster, Melissa; Kalvaitis, Katie; Murphy, Casey // Cardiology Today;Jan2012, Vol. 15 Issue 1, p17 

    The article focuses on a study which compared the effectiveness of apixaban with enoxaparin in preventing venous thromboembolism.

  • Primary androgen deprivation therapy does not prolong survival in most patients with prostate cancer.  // Formulary;Sep2008, Vol. 43 Issue 9, p341 

    The article focuses on the study which tests the effectiveness of primary androgen deprivation therapy (PADT) in treating patients with prostate cancer. Published in the "Journal of the American Medical Association," the study reveals that PADT can be associated with lower 10-year prostate...

  • New research raises questions about St. John's wort. Johnsen, Michael // Drug Store News;6/25/2001, Vol. 23 Issue 8, p127 

    Reveals that previous clinical trials that investigated the effectiveness of the antidepressant supplement Saint John's wort had significant design flaws, according to a study published in the April 18, 2001 issue of the `Journal of the American Medical Association.' Sponsors of the research;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics